Why the study?
Does sitagliptin improve flow-mediated dilatation compared to voglibose in patients with type 2 diabetes inadequately controlled on standard oral therapy?
Population
66 patients with type 2 diabetes who did not achieve the treatment goal with sulfonylurea, metformin or…
Comparison
Sitagliptin for 12 weeks vs Voglibose for 12 weeks
Design
RCT, randomized
Follow-up
12 weeks
Authors
Loading...
Both agents may be used interchangeably to improve endothelial function in T2DM; extends comparative evidence on DPP-4 versus alpha-glucosidase inhibition.
Does sitagliptin improve flow-mediated dilatation compared to voglibose in patients with type 2 diabetes inadequately controlled on standard oral therapy?
Sitagliptin and voglibose equally improve endothelial function in patients with type 2 diabetes, with sitagliptin showing a more favorable tolerability profile and increasing circulating CD34.
Nakamura et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: